Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations
about
Next-generation sequencing in thyroid cancerDual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitorCarfilzomib potentiates CUDC-101-induced apoptosis in anaplastic thyroid cancerTWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells.SP600125 has a remarkable anticancer potential against undifferentiated thyroid cancer through selective action on ROCK and p53 pathways.Ancestral experience as a game changer in stress vulnerability and disease outcomes.Notch1 Signaling Regulates the Aggressiveness of Differentiated Thyroid Cancer and Inhibits SERPINE1 Expression.The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.Radiotherapy in anaplastic thyroid carcinoma: An Australian experience.Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).Pharmacoepigenetics: an element of personalized therapy?NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinomacMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis.Anaplastic thyroid carcinoma: Failure of conventional therapy but hope of targeted therapy.The dipeptidyl peptidase-IV inhibitor gemigliptin alone or in combination with NVP-AUY922 has a cytotoxic activity in thyroid carcinoma cells.Effects of nutraceuticals on anaplastic thyroid cancer cells.8-Cl-cAMP and PKA I-selective cAMP analogs effectively inhibit undifferentiated thyroid cancer cell growth.
P2860
Q28079384-BCEB5838-3225-4990-9D10-8916FD13F433Q35622067-4BAB1048-36E4-4303-97EF-AF0D7930149AQ35945841-F7240739-733B-4F97-B3AF-BBCE6628CDE4Q37086070-10F5F1AD-9BB2-4818-A1D5-C2503686E061Q37688577-0D22DEF4-B328-432E-A2A9-1B5867DFD322Q38262971-B1FA287A-F35B-4110-954D-0EBCAA7A1F28Q38373478-DF0A800D-4D3A-4CC6-8E7C-DBEDC3AA6E7EQ38796455-41500C54-8042-42D6-8AAD-D0CFD1E4B703Q38848546-CC665CFF-CB28-4B8E-A969-A11377438946Q38848568-9E737F20-ADF4-4418-9D8B-C319F9468E8FQ38851509-3DD06CAF-A9C2-4538-9F96-54449A3DB349Q39012550-F33FFC0D-02DA-4DFF-A21A-88CD6B31B88AQ42014310-2E502EE5-6021-4C69-AA44-F420460EB5BEQ42281151-240199E4-0A1E-48C8-9193-74DD1623049FQ47631967-8BC291D0-0AE1-41EF-B3DD-EE03EB2E3CB6Q47691203-A7D878DA-F0FA-4D5C-815C-4029985F81C5Q48190761-C14E1D1B-FA8F-476B-9E41-D8617F881F01Q51615486-D87DAAA3-B0D8-4FC5-AE3A-6F97BE7FD18A
P2860
Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Personalized therapy in patien ...... tic and epigenetic alterations
@ast
Personalized therapy in patien ...... tic and epigenetic alterations
@en
Personalized therapy in patien ...... tic and epigenetic alterations
@nl
type
label
Personalized therapy in patien ...... tic and epigenetic alterations
@ast
Personalized therapy in patien ...... tic and epigenetic alterations
@en
Personalized therapy in patien ...... tic and epigenetic alterations
@nl
prefLabel
Personalized therapy in patien ...... tic and epigenetic alterations
@ast
Personalized therapy in patien ...... tic and epigenetic alterations
@en
Personalized therapy in patien ...... tic and epigenetic alterations
@nl
P2860
P356
P1476
Personalized therapy in patien ...... tic and epigenetic alterations
@en
P2093
Carmelo Nucera
Neal Smith
P2860
P356
10.1210/JC.2014-2803
P407
P577
2015-01-01T00:00:00Z